---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-024758"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-07-29T13:01:54+00:00"
generated_at: "2026-07-29T13:06:41.076748+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences surpasses enrollment midpoint in NANOPULSE-AF pivotal study

## Summary
- Study commenced April 2026; already past midpoint, enrolling at up to 30 sites including outside U.S.
- CMO David Kenigsberg cites strong enrollment trajectory reflecting investigator enthusiasm for nPulse technology.
- Top-enrolling investigator Frank Cuoco notes minimal learning curve and seamless workflow integration.
- Company to provide further commentary on study progress during August 6, 2026 earnings call.

## SEC filing metadata
- accession: 0001437749-26-024758
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-07-29T13:01:54+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926024758/0001437749-26-024758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926024758/plse20260728_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-024758
- JSON: https://secwatch.observer/filing/0001437749-26-024758.json
- Plain text: https://secwatch.observer/filing/0001437749-26-024758.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.